Scott Erickson
Family Medicine · Bountiful, UTNPI 1780681775
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,738 of the $100,938 with a category attached, or 77.0%. Alkermes, Inc. accounts for 84.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $36,463 and has fallen 65.8% since, to $12,453 in 2025. Among family medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $371.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$85K
- Indivior Inc.$13K
- MDD US Operations, LLC$2K
- AbbVie$112
- Braeburn Inc.$109
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$86
- plus $577 from 15 others
Across 270 payments — averaging $13,398 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$3.5M
- Sanofi Pasteur Inc.$120K
What the payments were for
- Consulting fees$3,5003%
- Speaking & faculty fees$77,73877%
- Travel & lodging$14,98815%
- Food & beverage$4,6995%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 154 | $85,352 |
| Indivior Inc. | 62 | $12,945 |
| MDD US Operations, LLC | 3 | $1,757 |
| AbbVie(2 entities) | 7 | $112 |
| Braeburn Inc. | 6 | $109 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $86 |
| Novo Nordisk | 5 | $76 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $72 |
| Idorsia Pharmaceuticals US Inc | 4 | $70 |
| Pfizer | 3 | $55 |
| Lilly USA, LLC | 4 | $53 |
| Eisai Inc. | 3 | $42 |
| Pear Therapeutics (US), Inc. | 2 | $40 |
| USWM, LLC | 2 | $34 |
| Kaleo, Inc. | 2 | $32 |
| Amgen | 1 | $23 |
| Genentech USA, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Gilead | 1 | $16 |
| Shire North American Group Inc | 1 | $13 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$82,793
- SUBLOCADE$11,786
- Lucemyra/Lofexidine$1,250
How this compares
$100,938 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tresiba Flextouch U-200Insulin Degludec | 28 | $15,909 |
| EliquisApixaban | 11 | $10,869 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 126 | $8,413 |
| Buprenorphine Hcl | 46 | $1,605 |
| Atorvastatin Calcium | 78 | $667 |
| Tamsulosin Hcl | 18 | $517 |
| Oxycodone Hcl | 27 | $431 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $389 |
| Omeprazole | 36 | $311 |
| Metformin Hcl | 28 | $223 |
| Duloxetine Hcl | 21 | $218 |
| Simvastatin | 19 | $210 |
| Trazodone Hcl | 23 | $209 |
| Eszopiclone | 19 | $208 |
| Clonazepam | 36 | $197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $55 | $10,86911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 928 family medicine providers in Utah.
Other family medicine in Bountiful
- Allen FreestoneBountiful$9K
- Michael CobbleSandy$1.3M
- Thomas ClarkProvidence$332K
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Mark CacciamaniSalt Lake City$43K
- Clint MowerLehi$41K
- Russell AndersonTooele$30K
- Kirk OdonnellSalt Lake City$23K
- John TemplemanProvo$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.